Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anhui Biox-Vision Biological Technology Co. Ltd. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit, reflecting a highly focused examination path. In the biotechnology field, this suggests a specific focus on a single biological or pharmaceutical innovation.
KATHLEEN MARY CUNNINGCHEN is the busiest examiner for the portfolio, currently overseeing 1 pending office action. This 1 busiest examiner pending action accounts for the total pending workload of the company. Practitioners should note that the prosecution progress for the entire portfolio is currently tied to this single examiner's review. The concentration in 1 distinct art unit indicates that the company is not currently managing cross-disciplinary filings that would require coordination across different pharmaceutical or biological examination groups at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715119 | BISPECIFIC ANTIBODY AGAINST CD40 AND CLDN18.2 AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715119 | BISPECIFIC ANTIBODY AGAINST CD40 AND CLDN18.2 AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715119 | BISPECIFIC ANTIBODY AGAINST CD40 AND CLDN18.2 AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §101§112DP | Non-Final OA | — | Pending | May 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnhui Biox-Vision Biological Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kathleen Mary Cunningchen has the most, with 1 of Anhui Biox-Vision Biological Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.